Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00

Key Points

• Truist Financial has lowered its price target for Regeneron Pharmaceuticals from $940.00 to $812.00 while maintaining a "buy" rating, suggesting a potential upside of 45.12% from the previous close.
• Regeneron reported a better-than-expected EPS of $12.89 for the recent quarter, surpassing consensus estimates by $4.46, and posted revenue of approximately $3.68 billion.
• The stock has received mixed ratings from analysts, with seven hold ratings, sixteen buy ratings, and a consensus rating of "Moderate Buy" at a target price of $835.74.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its target price decreased by stock analysts at Truist Financial from $940.00 to $812.00 in a report released on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the biopharmaceutical company's stock. Truist Financial's target price would suggest a potential upside of 45.12% from the company's previous close.

Several other research analysts have also weighed in on REGN. Wall Street Zen lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Morgan Stanley reiterated an "overweight" rating and set a $761.00 target price (up from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Robert W. Baird cut their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price target for the company. Finally, The Goldman Sachs Group reduced their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $835.74.

Regeneron Pharmaceuticals Trading Down 0.6%

NASDAQ:REGN traded down $3.47 on Monday, hitting $559.54. 200,157 shares of the stock were exchanged, compared to its average volume of 1,110,032. The stock has a market cap of $60.41 billion, a PE ratio of 14.10, a PEG ratio of 1.91 and a beta of 0.33. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The stock has a fifty day moving average of $536.80 and a 200-day moving average of $598.52.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. The business had revenue of $3,675,600 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. Regeneron Pharmaceuticals's revenue was up 3.6% compared to the same quarter last year. During the same period in the prior year, the business posted $11.56 earnings per share. As a group, equities analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Citizens Financial Group Inc. RI increased its stake in shares of Regeneron Pharmaceuticals by 237.4% during the second quarter. Citizens Financial Group Inc. RI now owns 2,659 shares of the biopharmaceutical company's stock worth $1,396,000 after purchasing an additional 1,871 shares in the last quarter. Westwood Holdings Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 17.0% in the second quarter. Westwood Holdings Group Inc. now owns 13,556 shares of the biopharmaceutical company's stock valued at $7,117,000 after buying an additional 1,974 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of Regeneron Pharmaceuticals by 5.9% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 25,469 shares of the biopharmaceutical company's stock valued at $13,371,000 after purchasing an additional 1,409 shares during the period. Grandfield & Dodd LLC boosted its position in shares of Regeneron Pharmaceuticals by 6.0% in the second quarter. Grandfield & Dodd LLC now owns 35,205 shares of the biopharmaceutical company's stock worth $18,483,000 after buying an additional 1,998 shares during the period. Finally, First Western Trust Bank lifted its stake in Regeneron Pharmaceuticals by 6.4% during the second quarter. First Western Trust Bank now owns 545 shares of the biopharmaceutical company's stock worth $286,000 after purchasing an additional 33 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.